Skip to main content

Table 3 Randomized controlled trials of neoadjuvant chemoradiotherapy versus surgery alone for esophageal squamous cell carcinoma

From: Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?

Study Histology SCC (%) Treatment n MS (months) 5-year OS (%) P value
Bosset and colleagues [30] SCC 100 C + 37 Gy 143 19 7 NS
    Surgery 139 19 9  
Lee and colleagues [32] SCC 100 CF + 45 Gy 51 28 49a NS
    Surgery 50 27 41a  
Burmeister and colleagues [34] AC/SCC 35 CF + 35 Gy 128 22 17 NS
    Surgery 128 19 13  
Natsugoe and colleagues [33] SCC 100 CF + 40 Gy 22   57 0.58
    Surgery 23   41  
Tepper and colleagues [35] AC/SCC 25 CF + 50.4 Gy 30 54 39 <0.01
    Surgery 26 21 16  
Mariette and colleagues [31] AC/SCC 66 CF + 45 Gy 97 32 49a 0.68
    Surgery 98 44 55a  
Gaast and colleagues [36] AC/SCC 24 PC + 41.4 Gy 175 49 59a 0.011
    Surgery 188 26 48a  
  1. aThree-year overall survival (OS). AC adenocarcinoma, C cisplatin, CF cisplatin + fluorouracil, MS median survival, NS not significant, PC paclitaxel + carboplatin, SCC squamous cell carcinoma.